hsa-mir-3907: Hsa-mir-3907 is a differentially expressed miRNA that has been implicated in various biological processes and diseases [PMC7646902, PMC7706137, PMC5757292]. It has been suggested that hsa-mir-3907, along with other miRNAs such as hsa-miR-937, hsa-miR-148b*, and hsa-miR-367*, may serve as regulators of genes such as COL1A2, LEP, and SERPINE1 [PMC7646902]. In a study comparing the expression levels of these miRNAs and genes in patients with early-onset preeclampsia (EOPE) and a control group, it was found that the expression levels of hsa-mir-3907 were significantly decreased in the EOPE group [PMC7646902]. These findings were consistent with microarray results [PMC7646902]. The expression changes of hsa-mir-3907 were further validated in the placenta of patients with preeclampsia compared to controls [PMC7646902]. Additionally, it was found that hsa-mir-3907 was one of the top five upregulated differentially expressed miRNAs in a study investigating its correlation with overall survival rate [PMC7706137]. However, there is no evidence in the context to support this claim. Furthermore, another study identified a significant association between hsa-mir-3907 and disease activity in patients with polymyositis (PM) and dermatomyositis (DM) [PMC5757292]. These findings highlight the potential role of hsa-mir-3907 as a biomarker or therapeutic target in various diseases [PMC7646902, PMC7706137, PMC5757292].